Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2017-11-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is titled as a "重大资产重组进展公告" which translates to "Major Asset Restructuring Progress Announcement." It discusses ongoing progress and updates related to a significant asset restructuring involving the company and its subsidiary. The document mentions multiple previous announcements and the continuation of stock suspension due to the restructuring process. It also states that the company will provide progress updates every five trading days until the restructuring plan is finalized. The document is relatively short (1206 characters) and serves as an update on the status of a major asset restructuring rather than the full details of the restructuring itself or a formal report. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as major asset restructurings.
2017-11-29 Chinese
重大资产重组继续停牌公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from 哈药集团股份有限公司 regarding the continuation of a trading suspension due to a major asset restructuring. It details the status of the restructuring, including ongoing negotiations, due diligence, and regulatory compliance, but does not contain financial statements or detailed financial data. The document is relatively short (2216 characters) and serves as a regulatory update on the progress and reasons for continued suspension of trading. It fits the category of a Capital/Financing Update (CAP) because it relates to a significant corporate financing event (major asset restructuring) and the impact on stock trading status.
2017-11-27 Chinese
八届二次董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a board resolution announcement from 哈药集团股份有限公司 regarding the continuation of a trading suspension due to a major asset restructuring involving an overseas listed company. It mentions the board meeting date, voting results, and the decision to apply for a trading suspension extension. There is no financial data, no detailed report, no earnings or audit information, and no shareholder voting results. The document is an official announcement of a board decision related to capital market activities but does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update directly. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-11-27 Chinese
重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is titled as a "重大资产重组进展公告" which translates to "Major Asset Restructuring Progress Announcement." It discusses ongoing progress and updates related to a significant asset restructuring involving the company and its subsidiary. The text mentions multiple previous announcements and the continuation of stock suspension due to the restructuring process. There is no detailed financial data or full report content, but rather a progress update and disclosure of ongoing activities and plans. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as major asset restructurings.
2017-11-22 Chinese
关于完成工商变更登记手续的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 哈药集团股份有限公司 regarding completion of industrial and commercial registration changes including company address, legal representative, and registered capital. It mentions board resolutions and shareholder meeting approvals but does not contain financial statements or detailed financial data. The document is short (737 characters) and serves as a formal notification of changes in company registration details rather than a full report or financial filing. This fits the category of Regulatory Filings (RNS) as it is a general regulatory announcement about corporate changes that do not fit other specific categories.
2017-11-22 Chinese
重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is titled as a '重大资产重组进展公告' which translates to 'Major Asset Restructuring Progress Announcement'. It discusses ongoing progress and updates related to a major asset restructuring involving the company's subsidiary. The text references previous announcements and states that the company will continue to disclose progress every five trading days. There is no detailed financial data or full report content, but rather an update on the status of a restructuring process. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as major asset restructurings.
2017-11-15 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.